by allowing Medicare, Medicaid to negotiate drug prices
Allow Medicare and Medicaid to negotiate drug prices.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
CMS says the Medicare Drug Price Negotiation Program has negotiated maximum fair prices for selected drugs, including the 10 drugs whose MFPs went into effect on January 1, 2026, and that the program will continue with later cycles in 2026 and 2027.
legacy_unverified · Source version not recorded · locator unknown
CMS says the GENEROUS Model aims to ensure fair and reasonable drug prices for Medicaid through CMS-led negotiations with drug manufacturers, with lower prices for participating state Medicaid programs.
legacy_unverified · Source version not recorded · locator unknown
Schrier’s issues page says the Inflation Reduction Act is law and that it gives Medicare the power to negotiate lower drug prices and cap Medicare out-of-pocket medication costs.
Assessments
The Medicare portion was delivered during Schrier's federal House tenure: the Inflation Reduction Act gave Medicare negotiation authority, and CMS has implemented negotiated prices effective January 1, 2026. The Medicaid portion has not been delivered as a broad statutory authority comparable to Medicare; CMS's 2026 GENEROUS model is voluntary and limited to participating states. Because the promise covered both Medicare and Medicaid, the outcome is partial rather than fully delivered.